Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients

Journal of Immunotherapy

Volumn 37, Issue 1, 2014, Pages 43-50

  Wang, Zibing ^a   Zhang, Yong ^a   Liu, Yuqing ^a   Wang, Li ^a   Zhao, Lingdi ^a   Yang, Tiejun ^a   He, Chaohong ^a   Song, Yongping ^b   Gao, Quanli ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine induced killer cells; Immunotherapy; Metastatic renal cell carcinoma; Myeloid derived; Suppressor cells; Tumor immunity

Indexed keywords

ALPHA INTERFERON; INDOMETACIN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DIARRHEA; FEMALE; FEVER; HUMAN; KIDNEY METASTASIS; LIVER TOXICITY; MALE; MIDDLE AGED; MYELOID DERIVED SUPPRESSOR CELL; NEPHROTOXICITY; PRIORITY JOURNAL; SUPPRESSOR CELL; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; CARCINOMA, RENAL CELL; CYTOKINE-INDUCED KILLER CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84890952595     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000005     Document Type: Article

References (36)

1. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13: 688-696.
2. Medical Research Council Renal Cancer Collaborators. Interferon- alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353: 14-17.
3. Huang YH, Zugates GT, Peng W, et al. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 2009;69: 6184-6191.
4. Li D, Zhang Y, Xie Y, et al. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Cancer Gene Ther. 2013;20: 251-259.
5. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004;101(suppl 2): 14639-14645. (Pubitemid 39346736)
6. Weber J, Atkins M, Hwu P, et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011;17: 1664-1673.
7. Li JJ, Gu MF, Pan K, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012;35: 189-195.
8. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther. 2012;12: 565-572.
9. Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokineinduced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12: 673-684.
10. Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18: 1751-1759.
11. Srivastava MK, Bosch JJ, Thompson JA, et al. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cellbased vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008;57: 1493-1504.
12. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloidderived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60: 1419-1430.
13. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61: 255-263.
14. Bonanno G, Iudicone P, Mariotti A, et al. Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine- induced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;8:129.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
16. Yu SS, Nukaya I, Enoki T, et al. In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method. Cancer Gene Ther. 2008;15: 508-516.
17. Wang Z, Jiang J, Li Z, et al. A myeloid cell population induced by Freund adjuvant suppresses T-cell-mediated antitumor immunity. J Immunother. 2010;33: 167-177.
18. Jiang J, Wang Z, Li Z, et al. Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression. Gene Ther. 2010;17: 991-999.
19. Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13:721s-726s.
20. DeVita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366: 2207-2214.
21. Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008;28: 3997-4002.
22. Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokineinduced killer cells. Anticancer Res. 2006;26: 2237-2242. (Pubitemid 43980179)
23. Kodumudi KN, Woan K, Gilvary DL, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16: 4583-4594.
24. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70: 3052-3061.
25. Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69: 2506-2513.
26. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70: 3526-3536.
27. Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11: 856-861.
28. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15: 2148-2157.
29. Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cellmediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14: 8270-8278.
30. Sinha P, Chornoguz O, Clements VK, et al. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011;117: 5381-5390.
31. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1): S55-S57.
32. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23: 133-141. (Pubitemid 41702632)
33. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338: 1272-1278. (Pubitemid 28216581)
34. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004;10: 6342S-6346S. (Pubitemid 39287489)
35. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15: 7412-7420.
36. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15: 7116-7118.